Pharmaceutical composition and application thereof

By adding synergistic components such as fatty acids and sterol esters to PI, the pharmaceutical composition is optimized, and the problems of insufficient solubility and high cost of PI are solved, and better drug effect and safety are achieved.

CN120478650APending Publication Date: 2025-08-15SUZHOU HAIYI BIOMEDICAL TECH CO LTD
2 Cites 0 Cited by

Patent Information

Application Number
CN202510896344.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-01
Publication Date
2025-08-15

AI Technical Summary

Technical Problem

The existing 1,4-polyisoprene (PI) has good solubility in solvents but no synergistic effects are considered, resulting in insufficient drug activity, high production cost, large usage, poor safety and compliance.

Method used

By adding synergistic components, including fatty acids and/or nonsterol fatty acid esters and sterols and/or sterol esters, the pharmaceutical composition of PI is optimized, the drug activity is enhanced and the amount of PI is reduced.

Benefits of technology

Improve drug effect under the same PI dose, reduce production costs, increase drug safety and compliance, and use refined animal and vegetable oils that meet food safety standards to prepare efficiencies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition and application thereof. The composition comprises a basic component and a synergistic component, wherein the basic component comprises 0.1-9.4 wt.% of 1, 4-polyisoprene; the synergistic component comprises a first synergistic component and a second synergistic component, and the content of the first synergistic component and the second synergistic component is 90.0-99.9 wt.%. The first synergistic component comprises fatty acid and / or non-sterol fatty acid ester, and the second synergistic component comprises sterol and / or sterol ester. On the basis of the total mass of the synergistic components, the first synergistic component is prepared from 64.0 to 99.9 weight percent of unsaturated fatty acid and / or non-sterol unsaturated fatty acid ester and 0 to 24.0 weight percent of saturated fatty acid and / or non-sterol saturated fatty acid ester; and the second synergistic component comprises 0.1 to 2.0 weight percent of sterol and / or sterol ester. According to the composition disclosed by the invention, the pharmaceutical activity of the 1, 4-polyisoprene is improved, and a better drug effect can be obtained under the condition of the same dosage.
Need to check novelty before this filing date? Find Prior Art